Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 16 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Koliou, Georgia-Angeliki  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Fountzilas, E., Kotoula V., Koliou G-A., Giannoulatou E., Gogas H., Papadimitriou C., et al. (2020).  Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.. Oncotarget. 11(1), 1-14.
Papaxoinis, G., Kotoula V., Giannoulatou E., Koliou G-A., Karavasilis V., Lakis S., et al. (2018).  Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.. Med Oncol. 35(7), 101.
Pectasides, E., Chatzidakis I., Kotoula V., Koliou G-A., Papadopoulou K., Giannoulatou E., et al. (2020).  Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.. Cancer Genomics Proteomics. 17(3), 277-290.
Economopoulou, P., Kotoula V., Koliou G-A., Papadopoulou K., Christodoulou C., Pentheroudakis G., et al. (2019).  Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.. Transl Oncol. 12(5), 739-748.
Koletsa, T., Kotoula V., Koliou G-A., Manousou K., Chrisafi S., Zagouri F., et al. (2020).  Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunol Immunother.
Fountzilas, E., Kotoula V., Tikas I., Manousou K., Papadopoulou K., Poulios C., et al. (2018).  Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.. Oncotarget. 9(86), 35623-35638.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.